M&A Deal Summary |
|
---|---|
Date | 2019-11-18 |
Target | Rodin Therapeutics |
Sector | Life Science |
Buyer(s) | Alkermes |
Deal Type | Add-on Acquisition |
Deal Value | 100M USD |
Advisor(s) | Goodwin Procter (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1987 |
Sector | Life Science |
Employees | 2,100 |
Revenue | 1.7B USD (2023) |
Alkermes is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases and oncology. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for diseases that include schizophrenia, depression, addiction, multiple sclerosis, and cancer. Alkermes was founded in 1987 and is based in Dublin, Ireland.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Add-on Acquisition) | 1 of 1 |
State (Massachusetts) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2019) | 1 of 1 |
Size (of disclosed) | 1 of 1 |